Cardiovascular adverse effects during itraconazole therapy

Fung, S-L., Chau, C-H., Yew, W-W.

Source: Eur Respir J 2008; 32: 240

Journal Issue: July

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Fung, S-L., Chau, C-H., Yew, W-W.. Cardiovascular adverse effects during itraconazole therapy. Eur Respir J 2008; 32: 240

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Adverse effects of anti-tuberculosis drugs in hemodialysis patients Source: International Congress 2019 – Tuberculosis and comorbidities Year: 2019
The safety of LAMA/LABA combination therapy for the ocular and urinary adverse effects in the COPD patients Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019
Cardiovascular side-effects of common antibiotics Source: Eur Respir Monogr 2020; 88: 264-278 Year: 2020
Adverse effects of moxifloxacin during tuberculosis treatment Source: Annual Congress 2012 - Pros and cons of MDR- and XDR-TB treatment Year: 2012
Severe adverse effects of antitubercular drugs and patient management Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011
Management of adverse drug events in TB therapy Source: Eur Respir Mon 2012; 58: 167-193 Year: 2012
Efficacy of diltiazem administration on the respiratory adverse effects of enalapril Source: Eur Respir J 2002; 20: Suppl. 38, 303s Year: 2002
The influencing of respiratory adverse effects of enalapril Source: Eur Respir J 2001; 18: Suppl. 33, 264s Year: 2001
Adverse effects analysis results during anti-TB treatment among hemodialysis patients Source: Virtual Congress 2021 – Challenges and advances in the diagnosis and clinical management of tuberculosis Year: 2021
Adverse anti-tuberculosis drug events and their management Source: Eur Respir Monogr 2018; 82: 205-227 Year: 2018
Low-dose amiodarone therapy may be responsible of serious adverse pulmonary effects in patients without pre-existing lung disease Source: Eur Respir J 2004; 24: Suppl. 48, 280s Year: 2004
Cardiovascular safety of long-term therapy with combination bronchodilator in patients with stable COPD Source: Eur Respir J 2004; 24: Suppl. 48, 290s Year: 2004
Cardiovascular effects of oral appliance treatment Source: 5th Sleep and Breathing Conference Year: 2019
Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events Source: Eur Respir J, 49 (5) 1602245; 10.1183/13993003.02245-2016 Year: 2017
Cardiovascular events related to the use of varenicline Source: Annual Congress 2012 - Tobacco cessation Year: 2012
Cardiovascular complications and norfenfluramine exposure with benfluorex use Source: Annual Congress 2008 - Pulmonary vascular medicine Year: 2008
Switching to nintedanib after discontinuation of pirfenidone due to adverse events in IPF Source: Eur Respir J 2015; 46: 1217-1221 Year: 2015
Frequent adverse events during prolonged Bedaquiline treatment on XDR-tuberculosis patients Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection II Year: 2019
Cardioprotective effects of inhaled corticosteroid-containing combination therapy in COPD Source: Eur Respir J, 53 (2) 1802420; 10.1183/13993003.02420-2018 Year: 2019